A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk.
Reduced diversity, as defined by homozygosity at each co-dominant HLA loci, might adversely affect the host's ability to recognize a more diverse array of foreign antigens and thereby increase subsequent disease burden. This concept is supported by a priori research that has examined effects of HLA zygosity on infectious disease, whereby a lack of HLA class I and II diversity has been associated with increased risk HIV and hepatitis B virus infection (6) (7) (8) .
Given the growing evidence that genetic variation within HLA genes play in the etiology of NHL subtypes (1-4, 9), we specifically aimed to test whether lack of HLA diversity -as measured by HLA homozygosity -was associated with increased NHL risk. Specifically, we posit that associations with HLA Class II, which primarily presents peptides derived from extracellular sources, would implicate a role in infectious disease etiology. On the other hand, associations with HLA Class I, which primarily presents peptides derived from intracellular sources, would suggest a role in related conditions, such as autoimmune or atopic conditions. We present here results from a pooled analysis of 25 studies from North America, Europe, and Australia where we measured the associations between HLA class I and/or class II zygosity and four main NHL subtypes.
MATERIALS AND METHODS
Study sample. Our study sample comprises the same study participants of European descent that were included in the original GWAS efforts from which 25 studies participated.
Specifically, adults diagnosed with incident, non-HIV-related B-cell NHL of mostly European descent, ascertained from cancer registries, clinics, or hospitals or through self-report were included and where diagnoses were verified by medical and pathology reports (1) (2) (3) (4) . Study designs included prospective cohort studies, population-and hospital-based case-control studies, and clinic-based studies. Original details of design methods for each study and of each GWAS have been described previously (1) (2) (3) (4) Final analytic sample. Data for HLA loci were directly imputed from the original GWAS SNP panels and evaluated for the 3,617 DLBCL, 2,686 FL, 2,878 CLL/SLL, 741 MZL, and 8,753 controls. We note that, as with the original GWAS manuscripts, the specific numbers of controls differed by NHL subtype, due to different study inclusion and control selection criteria for each NHL subtype analyses, as described by the original GWAS publications (enumerated in Table 2 ). Statistical analysis. Heterozygosity and homozygosity at each individual HLA locus and the number of homozygous loci for class I loci (A, B, C) and class II loci (DQB1, DRB1, DPB1) were determined; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as estimates of NHL risk with heterozygotes as the referent category, adjusted for sex, age, study, GWAS platform, and ancestry (with principal components as conducted for each subtypespecific GWAS and previously published (1) (2) (3) (4) . For analyses of MZL, adjustment by geographic region was conducted due to sample size restrictions (instead of by individual study). In addition to calculating the risk estimates for each additional number of homozygous loci, we further calculated the p-trend.
To further describe associations of zygosity by loci, we conducted joint effects analyses for HLA class I loci and class II loci. Each HLA loci (class I or II) was conducted in a stratified manner whereby heterozygotes for all loci were the referent groups and all combinations of homozygosity among the loci were evaluated. For example, to pinpoint whether HLA class I associations were attributable to HLA Class I B or C loci, we modeled as one covariate, 4 levels/combinations for HLA-B and -C (e.g., homozygous for both HLA-B and -C, homozygous only for HLA-B, homozygous for only HLA-C, and heterozygous for both), with heterozygote for both HLA-B and -C as reference ( Table 3) . For the associated p-trends reported in Table 3 , each category is modeled based on ordinal variable in the order listed in the table, with heterozygosity at all loci as the referent group in a logistic regression model. For each p-trend, we also present the linearized additive relative-risk-per-locus, reflecting the slope of the trend-line.
Platform-specific results are shown in a Supplemental Table 1 . Additional sensitivity analysis included evaluation of potential confounders, including evaluation of associations by previously implicated autoimmune conditions and HLA loci associated with specific NHL subtypes. We conducted stratified analysis to evaluate whether HLA zygosity associations were present among participants with and without autoimmune conditions (generally, and by specific conditions); similarly stratified analyses were conducted among participants with and without previously identified SNPs associated with NHL subtypes. We further calculated the risks, adjusting for autoimmune conditions and for all reported genetic susceptibility loci (for each NHL subtype). As neither variable altered the odds ratio >10%, those data are not presented.
Analyses that restricted studies to population-based controls only also did not have measurable effect on the results. Finally, to evaluate the probability that some of our results could be due to chance, we used the Benjamini-Hochberg method to calculate the false discovery rate (FDR) and applied it to the p-trends as this allows for the fewest number of comparisons and thus degrees of freedom to assess the additive model.
Unconditional logistic regression models were applied using SAS 9.4 (SAS Institute).
All tests of statistical significance were 2-sided.
RESULTS
The numbers of European cases and controls from each of the 25 studies in North America, Europe, and Australia for which HLA class I and II loci were evaluated are detailed in Table 1 .
DLBCL. Elevated DLBCL risks of 20-50% were observed for homozygosity for individual HLA class I (B and C) and/or class II loci (DRB1 and DQB1) ( Table 2) . DLBCL risk also increased with increasing number of homozygous class I loci (p-trend=0.0008; FDR p=0.003) and class II loci (p-trend<0.0001; FDR p=0.0005) ( Table 2) . Although homozygosity for HLA-A had a borderline non-significant effect for increasing DLBCL risk, joint analyses suggested that the 30% risk increase observed with two or more homozygote loci ( Table 2 ) was attributable to homozygosity at the HLA-B and -C locus (OR=1.31, 95% CI=1.06-1.60, Table 3 ).
Similarly, for class II loci, joint analysis showed statistically significant associations for homozygosity specifically at the HLA-DRB1 locus (OR=2.10, 95% CI=1.24-3.55) as significantly increased risk was observed only in combination with homozygous HLA-DRB1 locus ( Table 3) .
FL. There were no significant associations between zygosity at HLA class I loci and FL risk ( Table 2) . Statistically significant 24-54% increases, however, were observed for FL risk for Table 2) . Stratified analysis supported independent associations for both HLA-B and -C and MZL ( Table 3) . Homozygosity at HLA class II loci increased MZL risk ( Table 2) , but only the association with HLA-DRB1 reached statistical significance (OR=1.45, 95% CI-1.12-1.89, Table   2 ). Analyses considering single locus homozygosity provided evidence of a role for HLA-DRB1 in increasing MZL risk ( Table 3) CI=1.03-1.39) ( Table 2) . Increasing CLL/SLL risk was not observed with increasing number of homozygote class I or class II loci, though when evaluating total numbers of class I and II loci altogether, a borderline significant increased risk was observed for those with all five homozygote class I and II loci (OR=1.57, 95% CI=1.04-2.38, p-trend = 0.029; FDR=0.055) ( Table 2) . We were unable to isolate CLL/SLL associations with HLA zygosity to any singular locus ( Table 3) .
DISCUSSION
Based on the largest number of NHL subtypes to date for whom imputed HLA data is available, we demonstrate that HLA homozygosity plays a role in four B-cell NHL subtypes, and that the associations between homozygosity at HLA Class I and/or Class II loci are distinct by these subtypes. Specifically, FL risk was associated with homozygosity at HLA class II loci, but not Class I loci. CLL/SLL risk appeared to be associated (borderline) with homozygosity at either HLA Class I or Class II loci. In contrast, while both DLBCL and MZL were associated with zygosity at HLA Class I and Class II loci, the associations appeared specific to Class I HLA-B and -C loci and to the Class II HLA-DRB1 locus. We note that the p-trends evaluated for each additional homozygous loci remained statistically significant after adjust for multiple comparisons, with exception of that for CLL/SLL. Our results add to the growing body of literature implicating different roles for HLA class I and II loci, key modulators of human immune response, in the heterogeneous etiologies of B-NHL subtypes (1-4). Our results also add to the current literature which points to similarities in the etiologic profiles of DLBCL and MZL (13) . Overall, these data support the importance of HLA diversity in NHL etiology, with the type of HLA diversity potentially varying by NHL subtype.
The underlying hypothesis regarding the role of HLA zygosity and disease is that homozygosity at HLA loci reduces the diversity of peptides that can be presented, with the hypothesis that these peptides can reflect etiologic agents such as infectious diseases, selfantigens for atopic or autoimmune conditions, and even cancerous cells. At present, there is a growing body of literature supporting that HLA heterozygotes are more resistant to infectious diseases, and the corollary, that HLA homozygotes are more susceptible to infectious diseases. peptides to CD8+ cytotoxic T lymphocytes) has been demonstrated for slowing progression to AIDS (6) , whereas heterozygotes at HLA class II loci appear to have greater ability in clearing HBV infection (8) and HCV infection (14) than homozygotes. HLA-DRB1 heterozygosity has also been reported to confer favorable outcome (e.g., against end-stage liver disease) among HCV-infected liver transplant recipients (15) . There are also reports evaluating HLA zygosity as a key contributor in autoimmune conditions. For example, reports of heterozygote advantage for class II loci and inflammatory bowel disease (16) and for class I loci and psoriatic arthritis (17) have both been published. Specific associations between HLA zygosity and NHL have been Study strengths include the large sample size available to evaluate individual NHL subtypes which no studies have been able to do adequately to date (25) . Potential study limitations include possible misclassification of HLA alleles due to imputation, although direct comparison of a subset with genotyped HLA alleles showed >97% concordance (2) . While the present analysis leverages the available GWAS data through imputation of HLA alleles, we recognize that confirmation with direct HLA allelotyping may provide additional levels of information not ascertained in imputed data. 
etiology. Studies limitations also include our inability to evaluate heterogeneity within NHL subtypes, either defined molecularly, by infectious etiology, or by organ site.
In summary, our results add to the growing evidence of HLA alleles as susceptibility loci in the etiology of B-cell NHL subtypes. In addition to ongoing fine-mapping studies being conducted as follow-up to GWAS, our results here suggest that functional studies aiming to understand the underlying biology of zygosity and NHL subtype risk will also be important.
Additional efforts to evaluate larger-scale zygosity, such as of immune genes and perhaps the entire genome may prove important in understanding the full extent of the role diversity of the immune response plays in lymphoma etiology. Table 1 . Genome-wide association studies (GWAS) included in the evaluation of human leukocyte antigen (HLA) homozygosity and risk of four non-Hodgkin lymphoma (NHL) subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and marginal zone lymphoma (MZL). Table 2 : Effect of homozygosity at the three HLA class I loci -A, -B and -C and three HLA class II loci -DRB1, DQB1, and DPB1 on susceptibility to four NHL subtypes (DLBCL, FL, CLL/SLL, and MZL) in participants of European-descent within participating lymphoma genome-wide association studies (analyses adjusted for sex, study or region, age, and ancestry/principal components). Genome wide association studies (GWAS) included in the evaluation of human leukocyte antigen (HLA) homozygosity and risk of four non-Hodgkin  lymphoma (NHL) subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic 
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